Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Wedbush raised their Q1 2026 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research report issued on Thursday, July 31st. Wedbush analyst L. Chico now expects that the company will post earnings of $1.29 per share for the quarter, up from their prior forecast of $1.10. Wedbush has a "Outperform" rating and a $141.00 price target on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' FY2027 earnings at $9.24 EPS and FY2028 earnings at $10.72 EPS.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The firm had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. During the same quarter in the previous year, the company posted $1.63 earnings per share. The business's revenue was up 16.5% on a year-over-year basis.
NBIX has been the subject of several other research reports. HC Wainwright lowered their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Truist Financial began coverage on Neurocrine Biosciences in a research report on Monday, July 21st. They issued a "buy" rating and a $163.00 price objective for the company. Piper Sandler boosted their price objective on Neurocrine Biosciences from $154.00 to $175.00 and gave the company an "overweight" rating in a research report on Thursday. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research report on Thursday, July 10th. They issued a "buy" rating and a $182.00 price objective for the company. Finally, BMO Capital Markets upped their target price on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $160.90.
View Our Latest Research Report on Neurocrine Biosciences
Neurocrine Biosciences Stock Performance
Shares of NBIX stock opened at $128.91 on Monday. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.40. The stock has a 50 day moving average price of $128.26 and a two-hundred day moving average price of $120.74. The company has a market capitalization of $12.79 billion, a P/E ratio of 38.14, a PEG ratio of 1.11 and a beta of 0.25.
Insider Buying and Selling
In related news, insider Ingrid Delaet sold 457 shares of the company's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider directly owned 4,730 shares of the company's stock, valued at $638,550. This represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kevin Charles Gorman sold 9,613 shares of the company's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the sale, the director directly owned 514,596 shares in the company, valued at approximately $61,947,066.48. The trade was a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,251 shares of company stock valued at $11,672,602 over the last ninety days. Company insiders own 4.30% of the company's stock.
Institutional Investors Weigh In On Neurocrine Biosciences
A number of institutional investors have recently modified their holdings of NBIX. Dodge & Cox grew its stake in shares of Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock worth $612,129,000 after acquiring an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock worth $232,037,000 after acquiring an additional 640,556 shares during the last quarter. Orbimed Advisors LLC grew its stake in shares of Neurocrine Biosciences by 210.4% in the fourth quarter. Orbimed Advisors LLC now owns 938,120 shares of the company's stock worth $128,053,000 after acquiring an additional 635,900 shares during the last quarter. Swedbank AB grew its stake in shares of Neurocrine Biosciences by 5,078.9% in the first quarter. Swedbank AB now owns 429,697 shares of the company's stock worth $47,524,000 after acquiring an additional 421,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Neurocrine Biosciences by 1,405.2% in the first quarter. Assenagon Asset Management S.A. now owns 393,455 shares of the company's stock worth $43,516,000 after acquiring an additional 367,315 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.